COMMUNIQUÉS West-GlobeNewswire

Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million
27/06/2025
Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and [...]
PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET
26/06/2025
MINNEAPOLIS, MN, US, June 26, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion [...]
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
26/06/2025
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular [...]
Indacloud Unveils Top Premium THCA Flower Line
26/06/2025
Introducing Ice Cream Man, Skywalker OG Gold Edition, Red Velvet, Gold Cash Gold Edition, and Jedi Breath MADISON, Wis., June 26, 2025 (GLOBE NEWSWIRE) -- Parent Company, SERVD Distribution is proud to announce that [...]
EVA Pharma and BioPharma Town - Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement
26/06/2025
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office HANGZHOU, China and CAIRO, June 26, 2025 (GLOBE NEWSWIRE) -- EVA Pharma , one of the leading [...]
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
26/06/2025
Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation [...]
STENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb Preservation
26/06/2025
www.stentit.com Watch the video Click the White paper STENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb Preservation EINDHOVEN, The Netherlands – June [...]
Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon
26/06/2025
Oxford Healthspan’s Science-Backed, Food-Derived Spermidine Supplement Now Available at All Erewhon Locations SHERIDAN, Wyo., June 26, 2025 (GLOBE NEWSWIRE) -- Oxford Healthspan , a female-founded company dedicated to [...]
Press release: Transparency Notification from Shareholders
26/06/2025
Transparency Notification from Shareholders Ghent, Belgium – 26 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
XORTX Announces USD $925,000 Private Placement
26/06/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX [...]
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
26/06/2025
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well [...]
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
26/06/2025
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of [...]
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
26/06/2025
Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to [...]
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
26/06/2025
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today [...]
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
26/06/2025
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received [...]
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
26/06/2025
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company [...]
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
26/06/2025
Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. There are no available drugs targeting renal [...]
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
26/06/2025
Company in full compliance for continued listing MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company [...]
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
26/06/2025
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE’s [...]

Pages